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Abstract 
 Echinacea, a commonly used herbal supplement, is publicized for its antioxidant and 
immunostimulatory properties.  It has been used to treat the common cold and upper respiratory 
infections but has more recently been touted as a potential target for chemotherapeutic treatment.  
Echinacea is believed to work through the cannabinoid receptor 2 (CBR2), a G-protein coupled 
receptor primarily expressed in inflammatory and immune-competent cells.  Activation of CBR2 
is believed to induce the MAPK pathway as well as increase levels of cAMP.  Recent research 
has shown tumor expression of CBR2 which has been correlated to a decreased patient prognosis 
though the cellular pathway has not yet been elucidated.  This study was designed to gain a 
clearer understanding of the relationship between Echinacea, the cell cycle and CBR2. To assess 
the effect of Echinacea on cell growth, HeLa and human diploid fibroblast (HDF) cells were 
seeded and treated for 24 hours with 0, 25, 50 or 100 ug/ml of the water solubilized extract. The 
effect on cyclin A, cyclin E levels was assessed using the luciferase reporter assay. Additionally 
the presence of the CBR2 receptor was determined by using immunofluorescence and 
immunoblot analysis.  Our results show that cyclin activity appeared to be positively correlated 
to tumor cell proliferation following increased treatments of Echinacea.  Expression of CBR2 
was visualized using immunofluorescence and accumulated protein levels were assessed by 
imunoblot analysis. CBR2 was detected in both cell lines at varying levels. With these results it 
is hypothesized that the Echinacea may be activating CBR2 and inducing the MAPK pathway.  
In turn, the MAPK pathway activated the cyclins and caused increased cell proliferation. 
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Introduction 
Echinacea 
 A relative of the daisy, Echinacea purpurea is a species of Echinacea that is commonly 
used as an herbal supplement for its antioxidant, anti-inflammatory, and immunostimulatory 
properties (Wang et al, 2006). Though not certified by the FDA, Echinacea supplements can be 
found in both pill and oil form and are used in a variety of applications (Approved Drug Products 
with Therapeutic Equivalence Evaluations, 2005; Echinacea, 2012).  The supplements are 
regularly used as a remedy for upper respiratory tract infections, the common cold, as well as 
both bacterial and viral infections (Raduner et al, 2006).  Despite its widespread medicinal use,  
only a few studies have supported the clinical efficacy of Echinacea (Raduner et al, 2006).  
 Marlies et al (2014) examined the impact of Echinacea purpurea treatment for the 
common cold and concluded that there was a possible increase in prevention.  The study 
examined 24 clinical trials with various Echinacea preparations.  The preparations differed in 
both species of Echinacea as well as what part of the plant was used.  While some of the 
preparations were found to increase common cold prevention, the majority did not (Marlies et al 
2014).  In a review by Shah et al (2007) found there to be a decrease in the duration of the 
common cold in subjects who were treated with Echinacea (Shah et al, 2007).      
 Echinacea purpurea displays the qualities of an immune system stimulator.  It acts on the 
immune system by primarily affecting the innate immune system.  Echinacea treatment leads to 
both increased proliferation and activity in natural killer cells along with macrophage activation 
and increased phagocytic activity (Mistríková et al, 2006).  The immunostimulatory properties of 
Echinacea have led to its widespread use as an herbal supplement with chemotherapy for patients 
with cancer.  Over 50% of patients with cancer use herbal supplements to complement their 
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treatment with Echinacea being the most frequently used (Block et al, 2003). Lersch et al (1990) 
did investigate the clinical effectiveness of Echinacea supplementation on five patients with 
inoperable, advanced hepatocellular carcinomas.  While the study did find modest improvements 
both clinically and immunologically, there was no control in the study and the improvements 
could not be solely linked to Echinacea as the patients were also given a variety of other immune 
modulators (Lersch et al, 1990).   Interestingly, many of the phytochemicals of Echinacea are 
classified heptatoxic (Miller et al, 1998). 
 Contradictory to the popularity of the use of Echinacea as a complement to chemotherapy, 
Cichello et al (2015) revealed an increased proliferation of several cancers in vitro following 
Echinacea treatment.  HeLa cells and QBE-939 cells both displayed increased proliferation 
raising concerns about the possibility of Echinacea enhancing tumorgenesis (Cichello et al 
2015).  With Echinacea containing numerous compounds, there is little knowledge on which 
chemicals are mechanistically responsible for  stimulating cell proliferation. 
 The pharmacological compounds found in Echinacea can be separated into three distinct 
categories: alkylamides and polyenynes, caffeic acid derivatives, and polysaccharides 
(Mistríková et al, 2006).  Several studies have investigated the cellular mechanisms of the 
various compounds.  Huntimer et al (2006) treated HeLa cells with chicoric acid and cynarine, 
both phenolic compounds in Echinacea, and found increased cell growth (Huntimer et al, 2006).  
Gurtsch et al (2004) found alkylamides in Echinacea to upregulate TNF-alpha mRNA in primary 
human monocytes/macrophages presumably through interacting with the cannabinoid receptor 
type 2 (CBR2).  Additionally, it was found that alkylamides led to increased cAMP and activated 
JNK and p38/MPAK kinases.  Finally, it was suggested that the alkylamides activated ATF-
2/CREB-1 and NF-κB downstream (Gurtsch et al, 2004).  These stimulatory cellular mechanisms 
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are presumably modulated through the CBR2 receptor found on the immune cells.  Thus, its 
presence appears to play a vital role in the Echinacea signaling.  
 
CBR2 Receptor 
CBR2 is a 7-pass transmembrane G-protein coupled receptor that is similar in structure to 
the cannabinoid receptor type 1(CBR1).  CBR1 is found in high levels throughout the brain and 
has proven to be essential to behavior involving fear, anxiety and stress (Monory et al, 2015). 
CBR1 is also the target of THC, the main psychoactive constituent of cannabis (Sim-Selley et al, 
2003).  CBR2 has been identified on a wide array of cell types including keratinocytes, immune 
cells, microglia, perivascular cells, and more recently tumor cells (Romero-Sandoval et al, 2008; 
2009).  
The cannabinoid receptors are responsible for controlling many cell signaling events 
downstream.  CBR1 suppresses adenylate cyclase through an alpha inhibitory (αi) that inhibits 
cAMP-dependent pathways (Samson et al, 2003).  Via its Gβγ subunits, CBR1 is also able to 
impact downstream pathways that are independent of cAMP (Samson et al, 2003).  Gβγ is 
involved in signal transduction to phosphatidylinositol (PI) 3-kinase and mitogen-activated 
protein kinases (Samson et al, 2003).  CBR2 has been found to induce different downstream 
events.  Gertsch et al (2004), displayed that CBR2 agonists derived from Echinacea caused an 
increase in cAMP levels which were eliminated upon treatment with pertussis toxin (Gertsch et 
al, 2004).  This suggests that the CBR2 activation results in increases in cAMP levels in x cells.   
Transcriptionally, the cannabinoid receptors can regulate both CREB and NF-κB expression 
(Samson et al, 2003).  Romero-Sandoval et al (2009) concluded that CBR2 agonists cause 
inhibition of the extracellular signal-regulated kinase (ERK) through mitogen-activated protein 
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kinase-phosphatase (MAPK) induction.  Specifically, the expression of MKP-3 is increased 
resulting in a change from a pro-inflammatory microglial phenotype to an anti-inflammatory 
microglial phenotype (Romero-Sandoval et al, 2009).  
With the recent discovery of CBR2 expression in certain tumor cells, CBR2 is now being 
investigated as a potential therapeutic target.  Initial studies revealed that CBR2 agonists resulted 
in tumor cell growth inhibition; however, Perez-Gomez et al (2015) established that activation of 
Human Epidermal Growth Factor 2 (HER2) signaling via CBR2 correlated strongly with tumor 
progression and poor patient prognosis (Perez-Gomez, 2015).  Interestingly enough, CBR2 is not 
expressed in all tumors and even shows varying expression in tumors of the same cell type such 
as non-small cell lung cancer (NSCLC).  In patients suffering from NSCLC, only 55 percent 
were found to possess tumors expressing CBR2 according to IHC analysis.  It is known that 
NSCLC results in the overexpression of epidermal growth factor receptor (EGFR), which is 
thought to stimulate both cell proliferation and survival.  Preet et al (2011) showed metastasis in 
NSCLC cells treated with synthetic cannabinoids.  With these results it is hypothesized that 
CBR2 activation altered intracellular signaling pathways linked to EGFR (Preet et al, 2011).   
In this study investigated the effect of Echinacea on cell growth, cyclin expression, and 
separately discern the expression of CBR2 in five different cell lines: HeLa, 293T, HaCAT, 
HDF, and CV1.  It was found that Echinacea increased HeLa cell growth and that all cell lines 
expressed CBR2, though at different levels and variable staining pattern.  Cyclin E and A 
activity was examined to ascertain a possible cellular mechanism to explain the increased HeLa 
cell growth upon increasing treatments of Echinacea.  With cyclin levels mirroring the increase 
in proliferation upon increased Echinacea treatment, it was hypothesized that Echinacea is 
promoting tumor cell proliferation through the MAPK pathway. 
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Materials and Methods 
Cells and Cell lines.   
Monkey kidney fibroblast (CV1), human keratinocyte (HaCAT), human diploid fibroblasts 
(HDF), HeLa (cervical carcinoma), and 293T (human embryonic expressing SV40 T antigen) 
were maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% 
fetal bovine serum, 0.03% glutamine, containing 0.225% NaHCO3, 100 µg/ml streptomycin, and 
100 U/ml penicillin and grown at 37˚C with 5% CO2.  Cell lines were provided by Dr. M.J. 
Tevethia (PSU College of Medicine) and  Kathleen Rundell (NorthwwesternUniv) 
Immunofluorescence.  
Cells were seeded in duplicate at 6x105 cells per 60 mm dish containing 4 coverslips. When cells 
were 80% confluent, (approximately 24 hours) media was removed by aspiration and 
monolayers were washed 2 times with PBS (phosphate buffered saline). Cells were fixed to 
coverslips by incubation with a 50:50 solution of methanol:acetone.  After 5 minutes, fixative 
was removed and coverslips air-dried.   Coverslips were rehydrated for 2 minutes with PBS and 
then transferred to a new 60mm dish and 100ul of primary antibody (1:100 dilution in phosphate 
buffered saline (PBS) ) for the CBR2 (Santa Cruz Biotechnology), and/or SV40 T antigen 
(PAB901, kindly provided by Todd Schell, PSU HMC) was added. After 30 minutes at 37˚C and 
5% CO2, the slips were washed 3 times with PBS.  Secondary antibody (100ul, 1:200 dilution in 
PBS) with an attached FITC and/or rhodamine fluorochrome was added to the coverslips and 
incubated for 30 minutes at 37˚C.  Following incubation the dish containing coverslips was 
flooded and aspirated 3 times with PBS.  Lastly, the coverslips were washed with dH2O, air 
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dried and mounted with Vectashield containing DAPI. The coverslips were viewed using 
fluorescence microscopy.  
 
Western Blotting.  
Cells were lysed following the procedure outlined in Cavender et al 1999.  Briefly, a Bradford 
protein assay was performed and equal protein concentrations (100ug) were loaded into 4-20% 
PAGE gels. After electrophoresis the proteins were transferred to nitrocellulose using the iBlot 
(Invitrogen). Membranes were blocked with 5% non-fat dry milk and then subjected to Western 
blotting with anti-cannabinoid 2 receptor antibody (Santa Cruz Biotechnology) followed by 
detection with the Protein A conjugated to horseradish peroxidase (1:200 dilution in phosphate 
buffered saline (PBS) ) (Amersham).   Luminescence was generated using the Pierce Super 
Signal reagent (Thermo) and detected using the Genome digital capture device. 
 
Results 
  
 Upon treating the HeLa cells with varying concentrations of Echinacea, cell counts were 
obtained from four experiments done in triplicate in 12-well plates as seen in Figure 1.  With the 
0 µg/ml treatment there was an average cell count of 8.7x104 cells with a standard deviation of 
5.4x104.  With the 25µg/ml treatment there was an average cell count of 1.1x105 cells with a 
standard deviation of 6.9x104.  With the 50 µg/ml treatment there was an average cell count of 
1.3x105 cells with a standard deviation of 7.9x104.  With the 100 µg/ml there was an average cell 
count of 1.4x105 cells with a standard deviation of 1.0x105.  Significant increase in growth 
compared to the control was found in both 50µg/ml and 100 µg/ml Echinacea treatments of 
HeLa cells (p<0.05). 
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 After noting the increased cell proliferation following increased treatment of Echinacea, 
HeLa cells were treated with CBR2 antibody and placed under immunofluorescence to assess for 
CBR2 expression (Figure 2A).  The HeLa cells showed definitive CBR2 expression.  It was then 
hypothesized that CBR2 expression could be an artifact of cell culture and four other cell lines, 
293T, HaCaT, CV1, and HDF, were examined for CBR2 expression.  As seen in Figure 2B-E, 
293T, HaCAT, and CV1 cells all appeared to be expressing CBR2 with possible expression in 
HDF cells. 
 
 
 
 
 
 
 
Figure 1: Displays the average HeLa cell growth of 4 experiments done in 
triplicate in 12-well plates following varying treatments of Echinacea.  Stars 
denote significance with a p-value <0.05. 
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 To quantitatively asses CBR2 expression, a Western Blot analysis was performed as 
depicted in Figure 3.  The CBR2 band presented at approximately the 50kD protein marker.  
While all cells appeared to express some levels of CBR2, HeLa cells showed the highest 
expression with both 293T and HaCAT cells showing moderate expression.  CV1 cells showed 
minimal expression with HDF cells showing slightly less expression than the CV1 cells. 
 
 
 
 
Figure 2: Immunofluorescence at 40x magnification following treatment with CBR2 antibody in A: HeLa 
cells, B: 293T cells, C: HaCaT cells, D: CV1 cells, and E: HDF cells. All images captured with identical expose 
time. 
A B C
D E
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 With very little expression of the CBR2 receptor in the HDF cells, it was decided that a 
Luciferase assay would be performed on both HeLa cells and HDF cells to elucidate whether or 
not the Echinacea was stimulating cell growth through the CBR2 receptor.  If the proliferative 
properties of Echinacea were due to interactions with CBR2, then the Luciferase data for Cyclin 
A, Cyclin E, and p53 responsive element activation should display disparities in activation levels 
upon various treatments of Echinacea for the two cell lines.  p53 responsive element driving 
luciferase acted as the negative control for HeLa cells as they are p53 null.    
 With a previous increase in cell proliferation upon treatment with Echinacea, it was 
expected that the HeLa cells would show increased Cyclin A and Cyclin E activation upon 
increased treatment with Echinacea. This is due to Cyclin E being responsible for allowing the 
cell to progress into S phase and Cyclin A allowing the cell to progress through G2 phase and 
into Mitosis.  p53 responsive element, however, should act as a negative control in the HeLa 
cells and display no change in level of activation due to the ubiquitination of p53 that is caused 
from the Human Papilloma Virus with viral protein present in the HeLa cells.  It was 
hypothesized that if the increase in cell growth following Echinacea treatment was due 
interactions with the CBR2 receptor, then there should be no changes in Cyclin A, Cyclin E and 
Figure 3: Western Blot data following treatment with 
CBR2 antibody in A: CV1 cells, B: HeLa cells, C: HDF 
cells, D: 293T cells, and E: HaCaT cells. 
A B
50 kD 
C D E
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p53 responsive element activation  in the HDF cells upon varying treatments of Echinacea due to 
the lessened expression of CBR2 in the HDF cell line.   
 The results of 4 experiments in HeLa cells conducted in triplicate are seen in Figure 4.  As 
seen in Figure 4A, HeLa cells showed a 1.30 fold increase, a 1.44 fold increase, and a 1.50 fold 
increase in cyclin A activity at 25, 50, and 100µg/ml respectively  with both 50µg/ml and 
100µg/ml treatments showing significance (p<0.05).  As seen in Figure 4B, HeLa cells showed a 
1.16 fold increase, a 1.38 fold increase, and a 1.28 fold increase in cyclin E activity at 25, 50, and 
100µg/ml respectively though no treatments differed significantly from the control (p<0.05).  As 
seen in Figure 4C, HeLa cells showed a significant increase in p53 responsive element activity of 
1.16 fold only at 25µg/ml (p<0.05). 
 
 
 
 
Figure 4: Displays A: Cyclin A activation, B: Cyclin E 
activation, and C: p53 responsive element activation 
in HeLa cells in 4 experiments done in triplicate in 12-
well plates following treatments of Echinacea.  Stars 
denote significance with a P-value <0.05. 
A B
C
Cyclin A Activation in HeLa cells treated with 
Echinacea 
Cyclin E Activation in HeLa cells treated with 
Echinacea 
p53 Responsive Element Activation in HeLa cells 
treated with Echinacea 
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  The results of 4 experiments with HDF cells conducted in triplicate are seen in Figure 5. 
As seen in Figure 5A, HDF cells showed a 1.49 fold increase, a 1.24 fold increase, and a 1.50 
fold increase in cyclin A activity at 25, 50, and 100µg/ml respectively with no treatments 
differing significantly from the control (p<0.05).  As seen in Figure 5B, HDF cells showed a 
2.30 fold increase, a 4.44 fold increase, and a 6.57 fold increase in cyclin E at 25, 50, and 
100µg/ml respectively though no treatments differed significantly from the control (p<0.05).  As 
seen in Figure 5C HDF cells showed a 1.72 fold increase, a 2.46 fold increase, and a 2.41 fold 
increase in p53 responsive element activity at 25, 50, and 100µg/ml respectively with only the 
50µg/ml treatment differing significantly from the control (p<0.05). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Displays A: Cyclin A activation, B: Cyclin E 
activation, and C: p53 responsive element activation 
in HDF cells in 4 experiments done in triplicate in 12-
well plates following varying treatments of 
Echinacea.  Stars denote significance with a P-value 
A 
C
B
Cyclin A Activation in HDF cells treated with 
Echinacea 
Cyclin E Activation in HDF cells treated with 
Echinacea 
p53 Responsive Element Activation in HeLa cells 
treated with Echinacea 
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Discussion 
 
  This study investigated the effects of Echinacea on tumor cell growth, cyclin activity, and 
determined CBR2 expression in five different cell lines: HeLa, 293T, HaCAT, HDF, and CV1. 
With Echinacea complementation with chemotherapy being commonplace today as treatment for 
cancer, it is alarming that this study and others found Echinacea to be increasing proliferation in 
certain tumor cell lines.  As seen in Figure 1, upon treating HeLa cells with Echinacea, our 
results indicated a positive correlation between increased Echinacea treatment and increased cell 
proliferation.  Though tumor cell growth upon treatment with this suggested chemotherapeutic 
compliment is alarming, our findings were consistent with previous research (Cichello et al 
2015).    
 As seen in Figure 2, immunofluorescence utilizing CBR2 antibody treatment on HeLa, 
293T, HaCAT, CV1, and HDF cells revealed CBR2 expression in all cell lines with the 
exception of HDF cells which displayed possible expression.  A Western Blot assay, seen in 
Figure 3, correlated strongly with the immunofluorescence and confirmed CBR2 expression in 
all cell types.  These results were somewhat surprising.  CBR2 expression in 293T cells was not 
surprising as they are embryonic stem cells that have yet to differentiate.  Expression of CBR2 in 
the HaCaT cells was expected as they are keratinocytes and CBR2 is known to be expressed by 
keratinocytes.  Expression of CBR2 in HeLa cells was unexpected but not surprising as previous 
research has displayed CBR2 expression in certain tumor cell lines.  Expression of CBR2 in CV1 
and HDF cells was surprising as these two cell lines are not immune cells, stem cells, or 
tumorigenic thus that they should not be expressing the CBR2 receptor.   
 Our Luciferase data suggests a positive correlation between cellular proliferation and 
cyclin activity after treatment with Echinacea as seen in Figures 4 and 5.  Romero-Sandoval et al 
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(2009) showed that CBR2 activation induced the MAPK pathway.  Tying the two together 
allows for the postulated pathway, which can be seen in Figure 6.  It is proposed that a 
constituent molecule(s) of Echinacea could activate the CBR2 receptor.  The βγ subunits then 
activate the MAPK pathway.  The MAPK pathway is then responsible for inducing cyclin E 
activity leading to the activation of cyclin A and thus promoting cell growth.  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 To further elucidate the role that the CBR2 receptor plays in Echinacea signaling Western 
blotting can be utilized to assess for Akt phosphorylation and cyclic AMP can be monitored for 
increases or decreases to determine the downstream effects Echinacea has on CBR2 signaling.  
Additionally, cell counts must be taken to determine the effect of Echinacea treatment on HDF 
cell growth.  With wide variability in the Luciferase data, repeat experiments must be performed 
to obtain more concrete evidence of promoter activation in the HeLa and HDF cell lines. 
Cyclin Activity 
Cell Proliferation 
βγ α 
CBR2 
α 
Constituent 
molecule 
MAPK 
Figure 6: Displays the proposed cellular 
pathway causing cellular proliferation 
following Echinacea treatment on tumor 
cells. 
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 The increase in tumor cell growth following Echinacea treatment can finally be analyzed 
by performing Echinacea fractionation.  By separating the Echinacea into its constituent 
molecules, the constituent molecules responsible for the increased proliferation will be able to be 
exposed.  To do this the constituent molecules could be directly applied to the cells and a change 
in proliferation could be measured. 
Conclusions 
 With the widespread use of Echinacea supplementation as a complement to 
chemotherapeutic treatment in cancer patients, it should be of great concern that Echinacea 
treatment on tumor cells is causing increased proliferation.  Our data supports previous findings 
of increased cell proliferation in HeLa cells upon treatment with Echinacea further revealing the 
need for more research on the effects of Echinacea.  Our lab was able to definitively demonstrate 
CBR2 expression in several commonly used cell lines and is currently working to determine 
whether there is expression in the HDF cell line. While preliminary Luciferase data was not 
concrete, it does seem to suggest that the increased proliferation seen upon Echinacea treatment 
is, at least, partially caused by Echinacea interacting with CBR2. 
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